The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients

Table 1

Clinicopathological characteristics of DLBCL cases studied.

Variables	DLBCL; (); No (%)
Age
± SD	54.31 ± 16.07
Median	56.0
Range	2.0–87.0
<60	49 (58)
≥60	36 (42)
Gender
Male	42 (49)
Female	43 (51)
Primary site of involvement
Nodal	56 (66)
Extranodal	29 (34)
Number of involved extranodal sites
0	47 (55)
1-2	32 (38)
>2	6 (7)
Status
Generalized	16 (29)
Localized	40 (71)
Size (cm)
≤10	74 (87)
>10	11 (13)
Stage grouping
Early	48 (56)
Advanced	37 (44)
PS
<2	14 (16)
≥2	71 (84)
B symptoms
Present	51 (60)
Absent	34 (40)
LDH
Normal	11 (13)
Elevated	74 (87)
Prognostic group of R-IPI
Good	29 (34)
Poor	56 (66)
Risk groups of AAIPI ≥60
Low	6 (7)
Intermediate	16 (19)
High	17 (20)
Risk groups of AAIPI <60
Low	17 (20)
Intermediate	11 (13)
High	18 (21)
Type of DLBCL
Germinal	49 (57.6)
Nongerminal	36 (42.4)
Necrosis
Present	14 (16)
Absent	71 (84)
± SD	34.3 ± 22.4
Range	10.0–0.80
Mitosis
± SD	22.5 ± 9.5
Range	6.0–46.0
Media	21.0
Ki-67 LI
<50	50 (59)
≥50	35 (41)
Apoptosis
± SD	13.5 ± 6.4
Range	3.0–31.0
Median	13.0

R-IPI: revised international prognostic index; AAIPI: age adjusted international prognostic index.
PS: performance status; LDH: lactate dehydrogenase; Ki-67 LI: Ki-67 labeling index.
DLBCL: diffuse large B-cell lymphoma.